| Status | Awaiting development |
| Technology type | Medicine |
| Decision | None selected |
| Process | TA |
| ID number | 3853 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 18 December 2023 | Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during mid-May 2025 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid-July 2025. |
| 17 April 2023 | Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course. In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes. |
| 01 December 2022 | As you will be aware, the Department for Health & Social Care has asked NICE to conduct an appraisal of Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer. Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin in late October 2023 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid-January 2024. |
For further information on our processes and methods, please see our CHTE processes and methods manual